PX28700.P01										
			J.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE							
		TRANSMITTAL LETTER TO	U.S. APPLICATION NO. (If known, see 37 CFR							
		DESIGNATED/ELECTED (CONCERNING A FILING U	NDER 35 U.S.C. 371	15)						
10/553948										
INTERNATIONAL APPLICATION NO. PCT/JP2004/005935			INTERNATIONAL FILING DATE 23 April 2004	PRIORITY DATE CLAIMED 23 April 2003						
TITLE OF INVENTION METHYLATED C _P G POLYNUCLEOTIDE										
APPLICANT(S) FOR DO/EO/US Yukio SATO and Hiroko KOBAYASHI										
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information.										
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.								
3.	\boxtimes	This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (23) indicated below.								
4.		The US has been elected (PCT Article 31).								
	\square	☑ A copy of the International Application as filed (35 U.S.C. 371(c)(2))								
	a. 🔯 is attached hereto (required only if not communicated by the International Bureau).									
		 b. nas been communicated by c. is not required, as the application 	has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US).							
6.	\boxtimes	An English language translation of	the International Application as filed (35 U.S.C. 371 (c)(2)).						
		 a. ⊠ is attached hereto. b. ☐ has been previously submitted under 35 U.S.C. 154 (d) (4). 								
7.		Amendments to the claims of the li	nternational Application under PCT Ar	ticle 19 (35 U.S.C. 371(c)(3))						
		b. In have been communicated b	d only if not communicated by the Inte y the International Bureau.							
	 c. have not been made; however, the time limit for making such amendments has NOT expired. d. have not been made and will not be made. 									
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).								
9.	D. ☑ An oath or declaration of the inventor(s) (35 U.S.C371(c)(4)).									
		"UNEXECUTED"								
10.		An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
lt m	s 1	1 to 22 below concern other doc	ument(s) or information included:							
11. /	Ass	signee: YUKIO SATO, of Fukushim	a, JAPAN and Taisho Pharmaceutical	I Co., Ltd., of Tokyo, JAPAN						
12.	12. An Information Disclosure Statement under 37 CFR 1.97 and 1.98.									
13.	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.									
14.	\boxtimes	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.								
•	☐ An Application Data Sheet under 37 C.F.R. 1.76.									
	_	A substitute specification.								
	_	A power of attorney and/or change of address letter.								
		Figure of Drawing to be published: 1								
		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.								
		A second copy of the published international application under 35 U.S.C. 154 (d) (4).								
		A second copy of the English language translation of the international of the international application under 35 U.S.C. 154 (d) (4).								
	. ☑ Other items or information:									
	تع	International Application as pu	blished (in Japanese) with three shee	ts of Sequence Listings.						
PCT/RO/101 PCT Request Form (with International Application as filed in Japan and three sheets of Sequence Listings). Cover Letter under 35 U.S.C. 371 AND 37 C.F.R. 1.495.										
	PCT/IB/301. PCT/IB/304.									
	PC1/1B/304. PCT/IB/308.									
PCT/ISA/210 (in Japanese and English). PCT/ISA/237 (in Japanese).										
Thre Sheets of Sequence Listings.										
Claim of Priority.										

PX28700 P01

U.S. APPLICATION N	O. (If known, see 37	INTERNATIONAL API	PLICATION NO.	ATTORNEY'S DOCKET NUMBER						
CFR 1.5) 10/5	53948	PCT/JP2004/005935		P28700						
		·		CALCULATIONS	PTO USE ONLY					
	es are submitted:	300.00)	\$300.00						
24 🛛 Examination Fee If International prelimina		\$200.00								
provisions of PCT Article All other situations	33 (1)-(4)									
25 Search fee		\$400.00								
Search fee (37 CFR 1.44 an International Searching International Search Report All other situations	g Authority ort prepared and provided									
1	TOTAL 23, 24 and 25	\$0.00								
Additional Fee for S 100 sheets (excluding filed in electronic medi sheets of paper or frac	· sequence listing or cor um). The fee is \$250.0									
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE							
-100=	/50 =		× \$250.00	\$0.00						
Surcharge of \$130.00 to 30 months from the ea										
Claims	Number Filed	Number Extra	Rate							
Total Claims	9 - 20 =	0	× \$50.00	\$0.00						
Independent Claims	1 - 3=	0	× \$200.00	\$0.00						
Multiple Dependent Cla	aim(s) (if applicable)		+ \$360.00	\$0.00						
		TOTAL OF ABOVE C	ALCULATIONS =	\$900.00						
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by ½.										
		\$900.00								
Processing fee of \$130 from the earliest claims		\$0.00								
Extension of Time fee	in the amount of \$	\$0.00								
		\$900.00								
Fee for recording the e be accompanied by an property		\$0.00								
		\$900.00								
				Amount to be refunded	\$					
		Charged	\$							
a. A check in the an	nount of \$900.00 to co	ver the above fees is inc	luded.							
b. Please charge my Deposit Account Noin the amount of \$ to cover the above fees.										
c. The U.S. Patent and Trademark Office is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0089.										
d. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit car information and authorization on PTO-										
2038. NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
SEND ALL CORRESP	SEND ALL CORRESPONDENCE TO CUSTOMER NO. 07055 Leslie J. Paperner Laslie Mingrane									
AT THE PRESENT AD		Reg. No. 33,329	SIGNATURE U							
Bruce H. Bernstein GREENBLUM & BERNSTEIN, P.L.C. Bruce H. Bernstein										
1950 Roland Clark Pla	•			NAME	:111					
Reston, VA 20191										
(703) 716-1191		29,027 REGISTRATION NUMBER								

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Y. SATO et al. Mail Stop PCT

Appl. No: : Not Yet Assigned PCT Branch

I. A. Filed : 23 April 2004

(U.S. National Phase of PCT/JP2004/005935)

For : METHYLATED CpG POLYNUCLEOTIDE

CLAIM OF PRIORITY

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop PCT
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Applicant hereby claims the right of priority granted pursuant to 35 U.S.C. 119 and 365 based upon Japanese Application No. 2003-118999, filed 23 April 2003. The International Bureau already should have sent a certified copy of the Japanese application to the United Stated designated office. If the certified copy has not arrived, please contact the undersigned.

Respectfully submitted, Y. SATO et al.

200 ///

Bruce H. Bernsteir Reg. No. 29,027

Leslie J. Paperner Reg. No. 33,329

October 20, 2005 GREENBLUM & BERNSTEIN, P.L.C. 1950 Roland Clarke Place Reston, VA 20191 (703) 716-1191